DNA-scaffolded biomaterials enable modular and tunable control of cell-based cancer immunotherapies

Xiao Huang; Jasper Z. Williams; Ryan Chang; Zhongbo Li; Eric Gai; David M. Patterson; Yu Wei; Wendell A. Lim; Tejal A. Desai

The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/587105 doi: bioRxiv preprint CD69 in the presence of both HER2+ A375 cells and GFP+ AICE, and the activation was similar to T cells exposed to dual antigen target cells (human leukemia cell line K562 with GFP and HER2 co-expressed) (Fig. 4b) . For both CD4+ and CD8+ engineered primary T cells, we observed selective secretion of cytokines (IL-2 and IFN-γ, respectively) after 48 hours of co-culture with both HER2+ A375 cells and GFP+ AICE (Fig. 4c) . Increasing AICE GFP density led to elevated levels of cytokine secretion (Fig. 4c, Fig. Supplementary 4a) . Noticeably, T cells secreted significantly more cytokines with AICE presenting synNotch-priming GFP than with target cells presenting both synNotch and CAR antigens (A375 with GFP and HER2 co-expressed) (Fig. Supplementary 4b) .